N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development N-Zyme Biomedical announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of…
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD bioAffinity Technologies, Inc. a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor®, Inc., a targeted proteomic platform company, to…
Wiley Joins U.S. Department of Energy’s Genesis Mission Consortium to Advance AI-Powered Scientific Discovery Wiley announced its membership in the Genesis Mission Consortium, the public-private partnership supporting the U.S. Department of Energy’s (DOE) Genesis Mission, joining organizations including Nvidia, AWS,…
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics, Inc. a clinical-stage biotechnology company and a U.S.-based subsidiary of HLB, announced that the first participant has been dosed in the Phase 1…
illumiSonics and Sunnybrook Launch INOVAIT Focus Fund–Backed Clinical Trial Bringing Label-Free Laser Histology to Mohs Skin Cancer Surgery illumiSonics Inc., a medical technology company commercializing label-free tissue imaging, announced the launch of a prospective clinical validation study at Sunnybrook Health…
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA Bristol Myers Squibb a global biopharmaceutical leader, announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72…
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older Almirall, S.A. a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has…
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026 Meiji Seika Pharma Co., Ltd. announced that results from the global Phase III…
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies Takeda announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and…
IQVIA’s Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare…
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System Medifast, Inc. announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy…
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T…